Coverage requirement for the management and treatment of obesity
Summary
SF1053 requires health plan companies in Minnesota to cover the management and treatment of obesity. The required coverage must include evidence-based obesity treatments, specifically behavioral, dietary, and physical activity interventions; bariatric surgery; and FDA-approved medications used to treat obesity. The bill creates a new section in Minnesota Statutes chapter 62Q to apply this mandate to commercial health plans.
The bill also amends Minnesota’s Medical Assistance statute so that Medicaid coverage must include obesity treatment in the same manner required for private health plans under the new insurance mandate. Both provisions are set to take effect on January 1, 2026, and apply to health plans offered, issued, or renewed on or after that date.
Impact
The bill would expand mandated health coverage in Minnesota by requiring both private health insurers and Medical Assistance to cover obesity management and treatment. It adds a new insurance coverage requirement in chapter 62Q and ties Medicaid coverage to that same standard through an amendment to section 256B.0625. The practical effect would be to increase access to obesity-related care, including counseling, surgery, and prescription medications, while also increasing costs and administrative obligations for insurers and the state program.
Sentiment
The available record shows the bill was introduced and referred to the Senate Commerce and Consumer Protection Committee, but there are no recorded committee transcripts or votes in the provided materials. As a result, there is no direct evidence of debate, support, or opposition from the legislative record included here. The bill’s framing as a coverage mandate for evidence-based treatment suggests a public-health-oriented purpose, but the sentiment cannot be assessed beyond the fact of introduction and referral.
Contention
No specific points of contention are documented in the provided transcripts or voting history because none are available. Based on the bill’s subject matter, likely areas of debate would include whether obesity treatment should be a mandated benefit, the cost impact on premiums and Medical Assistance spending, and whether coverage should extend to surgery and anti-obesity medications. However, those concerns are not attributed to any named legislator or stakeholder in the materials provided.